Last reviewed 2026-04-20 · How we verify

Triumeq

Triumeq, marketed by St Stephens Aids Trust, is an established antiretroviral therapy with a key composition patent expiring in 2028. The drug's primary strength lies in its current market presence, leveraging its approved status and ongoing revenue generation. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic versions.

At a glance

Approved indications

No approved indications tracked.

Boxed warnings

• WARNING: HYPERSENSITIVITY REACTIONS, AND EXACERBATIONS OF HEPATITIS B Hypersensitivity Reactions Serious and sometimes fatal hypersensitivity reactions, with multiple organ involvement, have occurred with abacavir, a component of TRIUMEQ and TRIUMEQ PD (abacavir, dolutegravir, and lamivudine). Patients who carry the HLA ‑ B*5701 allele are at a higher risk of a hypersensitivity reaction to abacavir, although hypersensitivity reactions have occurred in patients who do not carry the HLA ‑ B*5701 a

Common side effects

• Insomnia
• Headache
• Fatigue
• Dizziness
• Nausea
• Diarrhea
• Depression
• Abnormal dreams

Serious adverse events

• Abacavir hypersensitivity reaction (serious/fatal)
• Dolutegravir hypersensitivity reaction
• Anaphylaxis
• Liver failure
• Renal failure
• Adult respiratory distress syndrome
• Respiratory failure
• Myolysis
• Death
• Erythema multiforme

Key clinical trials

• Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
• Research on the Psychological Status of Patients With HIV-1 Infection
• Triumeq in Amyotrophic Lateral Sclerosis (PHASE3)
• RolloverTreatment With Triumeq for People With ALS Following the Lighthouse II Trial (PHASE3)
• Antiretroviral Therapy for Acute and Chronic HIV Infection (PHASE3)
• Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals (PHASE4)
• Triumeq As an Integrase Single Tablet Regimen in People With HIV Who Inject Drugs (PHASE4)
• The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Triumeq CI brief — competitive landscape report
• Triumeq updates RSS · CI watch RSS
• St Stephens Aids Trust portfolio CI